REGENXBIO(US:RGNX) TMX Newsfile·2026-03-14 11:30Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. due to alleged violations of federal securities laws related to misleading statements about the efficacy and safety of its RGX-111 trial study [2][3]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in REGENXBIO between February 9, 2022, and January 27, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against REGENXBIO, with a deadline of April 14, 2026, for investors to seek the role of lead plaintiff [2]. Group 2: Company Performance and Stock Impact - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to a case of neoplasm in a trial participant, which also affected RGX-121 for MPS II [4]. - Following this announcement, REGENXBIO's stock price dropped by $2.40 per share, or 17.9%, closing at $11.01 per share [4]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [3].